Thermo Fisher – Mould Allergy Testing

Allergy to mould and successful AIT | Discover the connection

ImmunoCAP^® Allergen Components help you identify appropriate allergens for improved AIT outcomes.

Extract-based testing can be insufficient for diagnosis of mould sensitisation

• Standardisation of testing extracts is difficult.^1-3
• Sensitivity of SPT + slgE is less than 80%.⁴

A component test with Alt a 1 (Alternaria) alone has a sensitivity of 80%.⁵

“Precise diagnosis of fungal allergy is the basis for immunotherapy.” ⁶

Mould sensitisation correlates with asthma risk and severity

In a UK study 66% of adult asthma patients were found to be sensitised to mould.⁷

• Aspergillus 45%, Candida 36%, Penicillium 29%, Cladosporium 24%, Alternaria 22%, Botrytis 18%.

In US studies, a correlation between fungal exposure and asthma severity in sensitised children was shown: ^8,9

• Increased asthma symptoms.
• Increased exacerbation risk.

ImmunoCAP can help you improve AIT outcome

• AIT success is more likely if sensitisation to specific components is identified.^10-12
• Poly-sensitisation makes differentiation between specific and cross-reactive components a challenge. ^{10, 13, 14}
• ImmunoCAP Complete Allergens identify the allergen sources the patient is sensitised to, i.e. help rule in/out allergy. ^15-17
• ImmunoCAP Allergen Components differentiate between specific and cross-reactive sensitisation. ^10-12

References:

1. Aden E, et al. J Allergy Clin Immunol. 1999;104(1)128-35.
2. Vailes L, et al. J Allergy Clin Immunol. 2001;107(4):641-6.
3. Esch E. J Allergy Clin Immunol. 2004;113(2):210-5.
4. Kay B, et al. Allergy and allergic diseases. Vol 2. Blackwell Publishing 2008.
5. De Vouge MW, et al. Int Arch Allergy Immunol. 1996;111(4):385-95.
6. Twaroch TE, et al. Allergy Asthma Immunol Res. 2015;7(3):205-20.
7. O’Driscoll BR, et al. Clin Exp Allergy. 2009;39(11):1677-83.
8. Pongracic JA, et al. J Allergy Clin Immunol. 2010;125(3):593-9.
9. Gent JF, et al. Environ Res. 2012;118:86-93.
10. Canonica GW, et al. World Allergy Organization Journal 2013;6(1):17.
11. Asero R. Eur Ann Allergy Clin Immunol. 2012;44(5):183-7.
12. Schmid-Grendelmeier P. Hautarzt 2010;61(11):946-53.
13. Ciprandi G, et al. Eur Ann Allergy Clin Immunol. 2008;40(3):77-83.
14. Petersson CJ, et al. Sensitization profile in undiagnosed children with skin and respiratory allergy-like symptoms in primary care. Abstract presented at WAO, Buenos Aires, Argentina 6-10 December 2009.
15. Söderström L, et al. Allergy. 2003;58:921-8.
16. Sampson HA. J Allergy Clin Immunol. 2001;107:891-6.
17. Duran-Tauleria E, et al. Allergy. 2004;59(Suppl 78):35-41.

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.